Risk score = LncRNAs associated with doxorubicin metabolism can be used as molecular markers for immune microenvironment and immunotherapy in non-small cell lung cancer

Qianyi Lin; Ming Zhang; Ying Kong; Ziyuan Huang; Zhuoheng Zou; Zhuolong Xiong; Xiaolin Xie; Zitong Cao; Wanyi Situ; Jiaxin Dong; Shufang Li; Xiao Zhu; Yongmei Huang

doi:10.1016/j.heliyon.2023.e13811

Risk score = LncRNAs associated with doxorubicin metabolism can be used as molecular markers for immune microenvironment and immunotherapy in non-small cell lung cancer

Heliyon. 2023 Feb 17;9(3):e13811. doi: 10.1016/j.heliyon.2023.e13811. eCollection 2023 Mar.

Authors

Affiliations

¹ The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China.
² Department of Physical Medicine and Rehabilitation, Zibo Central Hospital, Zibo 255000, China.
³ Department of Clinical Laboratory, Hubei Province No.3 People's Hospital, Wuhan 430030, China.

Abstract

Doxorubicin is the most effective anthracycline chemotherapy drug in the treatment of cancer, and it is an effective single agent in the treatment of non-small cell lung cancer (NSCLC). There is a lack of studies on the differentially expressed doxorubicin metabolism-related lncRNAs in NSCLC. In this study, we extracted related genes from the TCGA database and matched them with lncRNAs. Doxorubicin metabolism-related lncRNA-based gene signatures (DMLncSig) were gradually screened from univariate regression, LASSO regression, and multivariate regression analysis, and the risk score model was constructed. These DMLncSig were subjected to a GO/KEGG analysis. We then used the risk model to construct the TME model and analyze drug sensitivity. The IMvigor 210 immunotherapy model was cited for validation. Eventually, we performed tumor stemness index differences, survival, and clinical correlation analyses.

Keywords: Doxorubicin; Immunotherapy; Molecular marker; Non-small cell lung cancer; Tumor microenvironment; lncRNAs.